Industry Research Reports
Home > Reports > Service & Software > Global Multi-Cancer Early Screening Market Research Report 2026
Global Multi-Cancer Early Screening Market Research Report 2026
Industry: Service & Software
Published Date: 2026-03-12
Pages: 155 Pages
Report ld: 6233490
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Multi-Cancer Early Screening Market Size(US$)
CAGR 2026-2032
17.0%
Market Size,2032
USD 3,858
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 1,504 million
Market Forecast in 2032(Value)
US$ 3,858 million
CAGR
17.0%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Multi-Cancer Early Screening market was valued at US$ 1305 million in 2025 and is anticipated to reach US$ 3858 million by 2032, at a CAGR of 17.0% from 2026 to 2032.
Multi-Cancer Early Screening is an early screening technology that simultaneously evaluates the risk of multiple cancers through a single test (such as a blood sample). Its core value lies in breaking through the limitations of traditional cancer screening (such as single cancer detection, invasive procedures, etc.), achieving "one tube of blood to test multiple cancers", significantly improving the early detection rate of cancer, and reducing the late diagnosis rate and mortality rate.
The North American market for Multi-Cancer Early Screening is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Multi-Cancer Early Screening is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Multi-Cancer Early Screening in Medical Institutions is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Multi-Cancer Early Screening include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life, Berry Genomics, Singlera Genomics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Multi-Cancer Early Screening market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Multi-Cancer Early Screening. The Multi-Cancer Early Screening market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Multi-Cancer Early Screening market comprehensively. Regional market sizes by Type, by Application, by Commercial Mode, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Multi-Cancer Early Screening manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
MARKET SEGMENTATION
By Company
- Guardant Health
- Exact Sciences
- Freenome
- Epiginomics AG
- Bio-techne
- ThriveEarlier Detection
- GRAIL, Inc.
- CellMax life
- Berry Genomics
- Singlera Genomics
- Geneseeq
- BGI Genomics
- Burning Rock Biotech Limited
- New Horizon Health Limited
- Yeasen Bio
- Hangzhou Aoru Biotech
- Amoy Diagnostics Co., Ltd.
- Genetron Health
- AnchorDx
- Surexam Bio-Tech Co.,Ltd.
- HaploX
- HefeiLaierBiotechnologyCo.,Ltd
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- cfDNA Methylation
- Low-pass WGS
- Protein Marker Combination
- Multi-omics Integrated Analysis
Segment by Application
- Medical Institutions
- Physical Examination Centers
Segment by Category
- IVD（In Vitro Diagnostics）
- LDT (Laboratory Developed Test)
CHAPTER OUTLINE
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Commercial Mode, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Multi-Cancer Early Screening companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multi-Cancer Early Screening Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 cfDNA Methylation
1.2.3 Low-pass WGS
1.2.4 Protein Marker Combination
1.2.5 Multi-omics Integrated Analysis
1.3 Market by Commercial Mode
1.3.1 Global Multi-Cancer Early Screening Market Size Growth Rate by Commercial Mode: 2021 vs 2025 vs 2032
1.3.2 IVD（In Vitro Diagnostics）
1.3.3 LDT (Laboratory Developed Test)
1.4 Market by Application
1.4.1 Global Multi-Cancer Early Screening Market Growth by Application: 2021 vs 2025 vs 2032
1.4.2 Medical Institutions
1.4.3 Physical Examination Centers
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Multi-Cancer Early Screening Market Perspective (2021–2032)
2.2 Global Multi-Cancer Early Screening Growth Trends by Region
2.2.1 Global Multi-Cancer Early Screening Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Multi-Cancer Early Screening Historic Market Size by Region (2021–2026)
2.2.3 Multi-Cancer Early Screening Forecasted Market Size by Region (2027–2032)
2.3 Multi-Cancer Early Screening Market Dynamics
2.3.1 Multi-Cancer Early Screening Industry Trends
2.3.2 Multi-Cancer Early Screening Market Drivers
2.3.3 Multi-Cancer Early Screening Market Challenges
2.3.4 Multi-Cancer Early Screening Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multi-Cancer Early Screening Players by Revenue
3.1.1 Global Top Multi-Cancer Early Screening Players by Revenue (2021–2026)
3.1.2 Global Multi-Cancer Early Screening Revenue Market Share by Players (2021–2026)
3.2 Global Top Multi-Cancer Early Screening Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Multi-Cancer Early Screening Revenue
3.4 Global Multi-Cancer Early Screening Market Concentration Ratio
3.4.1 Global Multi-Cancer Early Screening Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multi-Cancer Early Screening Revenue in 2025
3.5 Global Key Players of Multi-Cancer Early Screening Head Offices and Areas Served
3.6 Global Key Players of Multi-Cancer Early Screening, Products and Applications
3.7 Global Key Players of Multi-Cancer Early Screening, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Multi-Cancer Early Screening Breakdown Data by Type
4.1 Global Multi-Cancer Early Screening Historic Market Size by Type (2021–2026)
4.2 Global Multi-Cancer Early Screening Forecasted Market Size by Type (2027–2032)
5 Multi-Cancer Early Screening Breakdown Data by Application
5.1 Global Multi-Cancer Early Screening Historic Market Size by Application (2021–2026)
5.2 Global Multi-Cancer Early Screening Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Multi-Cancer Early Screening Market Size (2021–2032)
6.2 North America Multi-Cancer Early Screening Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Multi-Cancer Early Screening Market Size by Country (2021–2026)
6.4 North America Multi-Cancer Early Screening Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multi-Cancer Early Screening Market Size (2021–2032)
7.2 Europe Multi-Cancer Early Screening Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Multi-Cancer Early Screening Market Size by Country (2021–2026)
7.4 Europe Multi-Cancer Early Screening Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Multi-Cancer Early Screening Market Size (2021–2032)
8.2 Asia-Pacific Multi-Cancer Early Screening Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Multi-Cancer Early Screening Market Size by Region (2021–2026)
8.4 Asia-Pacific Multi-Cancer Early Screening Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Multi-Cancer Early Screening Market Size (2021–2032)
9.2 Latin America Multi-Cancer Early Screening Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Multi-Cancer Early Screening Market Size by Country (2021–2026)
9.4 Latin America Multi-Cancer Early Screening Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multi-Cancer Early Screening Market Size (2021–2032)
10.2 Middle East & Africa Multi-Cancer Early Screening Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2021–2026)
10.4 Middle East & Africa Multi-Cancer Early Screening Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Guardant Health
11.1.1 Guardant Health Company Details
11.1.2 Guardant Health Business Overview
11.1.3 Guardant Health Multi-Cancer Early Screening Introduction
11.1.4 Guardant Health Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.1.5 Guardant Health Recent Development
11.2 Exact Sciences
11.2.1 Exact Sciences Company Details
11.2.2 Exact Sciences Business Overview
11.2.3 Exact Sciences Multi-Cancer Early Screening Introduction
11.2.4 Exact Sciences Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.2.5 Exact Sciences Recent Development
11.3 Freenome
11.3.1 Freenome Company Details
11.3.2 Freenome Business Overview
11.3.3 Freenome Multi-Cancer Early Screening Introduction
11.3.4 Freenome Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.3.5 Freenome Recent Development
11.4 Epiginomics AG
11.4.1 Epiginomics AG Company Details
11.4.2 Epiginomics AG Business Overview
11.4.3 Epiginomics AG Multi-Cancer Early Screening Introduction
11.4.4 Epiginomics AG Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.4.5 Epiginomics AG Recent Development
11.5 Bio-techne
11.5.1 Bio-techne Company Details
11.5.2 Bio-techne Business Overview
11.5.3 Bio-techne Multi-Cancer Early Screening Introduction
11.5.4 Bio-techne Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.5.5 Bio-techne Recent Development
11.6 ThriveEarlier Detection
11.6.1 ThriveEarlier Detection Company Details
11.6.2 ThriveEarlier Detection Business Overview
11.6.3 ThriveEarlier Detection Multi-Cancer Early Screening Introduction
11.6.4 ThriveEarlier Detection Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.6.5 ThriveEarlier Detection Recent Development
11.7 GRAIL, Inc.
11.7.1 GRAIL, Inc. Company Details
11.7.2 GRAIL, Inc. Business Overview
11.7.3 GRAIL, Inc. Multi-Cancer Early Screening Introduction
11.7.4 GRAIL, Inc. Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.7.5 GRAIL, Inc. Recent Development
11.8 CellMax life
11.8.1 CellMax life Company Details
11.8.2 CellMax life Business Overview
11.8.3 CellMax life Multi-Cancer Early Screening Introduction
11.8.4 CellMax life Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.8.5 CellMax life Recent Development
11.9 Berry Genomics
11.9.1 Berry Genomics Company Details
11.9.2 Berry Genomics Business Overview
11.9.3 Berry Genomics Multi-Cancer Early Screening Introduction
11.9.4 Berry Genomics Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.9.5 Berry Genomics Recent Development
11.10 Singlera Genomics
11.10.1 Singlera Genomics Company Details
11.10.2 Singlera Genomics Business Overview
11.10.3 Singlera Genomics Multi-Cancer Early Screening Introduction
11.10.4 Singlera Genomics Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.10.5 Singlera Genomics Recent Development
11.11 Geneseeq
11.11.1 Geneseeq Company Details
11.11.2 Geneseeq Business Overview
11.11.3 Geneseeq Multi-Cancer Early Screening Introduction
11.11.4 Geneseeq Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.11.5 Geneseeq Recent Development
11.12 BGI Genomics
11.12.1 BGI Genomics Company Details
11.12.2 BGI Genomics Business Overview
11.12.3 BGI Genomics Multi-Cancer Early Screening Introduction
11.12.4 BGI Genomics Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.12.5 BGI Genomics Recent Development
11.13 Burning Rock Biotech Limited
11.13.1 Burning Rock Biotech Limited Company Details
11.13.2 Burning Rock Biotech Limited Business Overview
11.13.3 Burning Rock Biotech Limited Multi-Cancer Early Screening Introduction
11.13.4 Burning Rock Biotech Limited Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.13.5 Burning Rock Biotech Limited Recent Development
11.14 New Horizon Health Limited
11.14.1 New Horizon Health Limited Company Details
11.14.2 New Horizon Health Limited Business Overview
11.14.3 New Horizon Health Limited Multi-Cancer Early Screening Introduction
11.14.4 New Horizon Health Limited Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.14.5 New Horizon Health Limited Recent Development
11.15 Yeasen Bio
11.15.1 Yeasen Bio Company Details
11.15.2 Yeasen Bio Business Overview
11.15.3 Yeasen Bio Multi-Cancer Early Screening Introduction
11.15.4 Yeasen Bio Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.15.5 Yeasen Bio Recent Development
11.16 Hangzhou Aoru Biotech
11.16.1 Hangzhou Aoru Biotech Company Details
11.16.2 Hangzhou Aoru Biotech Business Overview
11.16.3 Hangzhou Aoru Biotech Multi-Cancer Early Screening Introduction
11.16.4 Hangzhou Aoru Biotech Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.16.5 Hangzhou Aoru Biotech Recent Development
11.17 Amoy Diagnostics Co., Ltd.
11.17.1 Amoy Diagnostics Co., Ltd. Company Details
11.17.2 Amoy Diagnostics Co., Ltd. Business Overview
11.17.3 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Introduction
11.17.4 Amoy Diagnostics Co., Ltd. Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.17.5 Amoy Diagnostics Co., Ltd. Recent Development
11.18 Genetron Health
11.18.1 Genetron Health Company Details
11.18.2 Genetron Health Business Overview
11.18.3 Genetron Health Multi-Cancer Early Screening Introduction
11.18.4 Genetron Health Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.18.5 Genetron Health Recent Development
11.19 AnchorDx
11.19.1 AnchorDx Company Details
11.19.2 AnchorDx Business Overview
11.19.3 AnchorDx Multi-Cancer Early Screening Introduction
11.19.4 AnchorDx Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.19.5 AnchorDx Recent Development
11.20 Surexam Bio-Tech Co.,Ltd.
11.20.1 Surexam Bio-Tech Co.,Ltd. Company Details
11.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
11.20.3 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Introduction
11.20.4 Surexam Bio-Tech Co.,Ltd. Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.20.5 Surexam Bio-Tech Co.,Ltd. Recent Development
11.21 HaploX
11.21.1 HaploX Company Details
11.21.2 HaploX Business Overview
11.21.3 HaploX Multi-Cancer Early Screening Introduction
11.21.4 HaploX Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.21.5 HaploX Recent Development
11.22 HefeiLaierBiotechnologyCo.,Ltd
11.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Details
11.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
11.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Introduction
11.22.4 HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-Cancer Early Screening Business (2021–2026)
11.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Multi-Cancer Early Screening Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of cfDNA Methylation
Table 3. Key Players of Low-pass WGS
Table 4. Key Players of Protein Marker Combination
Table 5. Key Players of Multi-omics Integrated Analysis
Table 6. Global Multi-Cancer Early Screening Market Size Growth Rate by Commercial Mode (US$ Million): 2021 vs 2025 vs 2032
Table 7. Key Players of IVD（In Vitro Diagnostics）
Table 8. Key Players of LDT (Laboratory Developed Test)
Table 9. Global Multi-Cancer Early Screening Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 10. Global Multi-Cancer Early Screening Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 11. Global Multi-Cancer Early Screening Market Size by Region (US$ Million), 2021–2026
Table 12. Global Multi-Cancer Early Screening Market Share by Region (2021–2026)
Table 13. Global Multi-Cancer Early Screening Forecasted Market Size by Region (US$ Million), 2027–2032
Table 14. Global Multi-Cancer Early Screening Market Share by Region (2027–2032)
Table 15. Multi-Cancer Early Screening Market Trends
Table 16. Multi-Cancer Early Screening Market Drivers
Table 17. Multi-Cancer Early Screening Market Challenges
Table 18. Multi-Cancer Early Screening Market Restraints
Table 19. Global Multi-Cancer Early Screening Revenue by Players (US$ Million), 2021–2026
Table 20. Global Multi-Cancer Early Screening Market Share by Players (2021–2026)
Table 21. Global Top Multi-Cancer Early Screening Players by Tier (Tier 1, Tier 2, and Tier 3), based on Multi-Cancer Early Screening Revenue, 2025
Table 22. Ranking of Global Top Multi-Cancer Early Screening Companies by Revenue (US$ Million) in 2025
Table 23. Global 5 Largest Players Market Share by Multi-Cancer Early Screening Revenue (CR5 and HHI), 2021–2026
Table 24. Global Key Players of Multi-Cancer Early Screening, Headquarters and Area Served
Table 25. Global Key Players of Multi-Cancer Early Screening, Products and Applications
Table 26. Global Key Players of Multi-Cancer Early Screening, Date of General Availability (GA)
Table 27. Mergers and Acquisitions, Expansion Plans
Table 28. Global Multi-Cancer Early Screening Market Size by Type (US$ Million), 2021–2026
Table 29. Global Multi-Cancer Early Screening Revenue Market Share by Type (2021–2026)
Table 30. Global Multi-Cancer Early Screening Forecasted Market Size by Type (US$ Million), 2027–2032
Table 31. Global Multi-Cancer Early Screening Revenue Market Share by Type (2027–2032)
Table 32. Global Multi-Cancer Early Screening Market Size by Application (US$ Million), 2021–2026
Table 33. Global Multi-Cancer Early Screening Revenue Market Share by Application (2021–2026)
Table 34. Global Multi-Cancer Early Screening Forecasted Market Size by Application (US$ Million), 2027–2032
Table 35. Global Multi-Cancer Early Screening Revenue Market Share by Application (2027–2032)
Table 36. North America Multi-Cancer Early Screening Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. North America Multi-Cancer Early Screening Market Size by Country (US$ Million), 2021–2026
Table 38. North America Multi-Cancer Early Screening Market Size by Country (US$ Million), 2027–2032
Table 39. Europe Multi-Cancer Early Screening Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 40. Europe Multi-Cancer Early Screening Market Size by Country (US$ Million), 2021–2026
Table 41. Europe Multi-Cancer Early Screening Market Size by Country (US$ Million), 2027–2032
Table 42. Asia-Pacific Multi-Cancer Early Screening Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 43. Asia-Pacific Multi-Cancer Early Screening Market Size by Region (US$ Million), 2021–2026
Table 44. Asia-Pacific Multi-Cancer Early Screening Market Size by Region (US$ Million), 2027–2032
Table 45. Latin America Multi-Cancer Early Screening Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Latin America Multi-Cancer Early Screening Market Size by Country (US$ Million), 2021–2026
Table 47. Latin America Multi-Cancer Early Screening Market Size by Country (US$ Million), 2027–2032
Table 48. Middle East & Africa Multi-Cancer Early Screening Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 49. Middle East & Africa Multi-Cancer Early Screening Market Size by Country (US$ Million), 2021–2026
Table 50. Middle East & Africa Multi-Cancer Early Screening Market Size by Country (US$ Million), 2027–2032
Table 51. Guardant Health Company Details
Table 52. Guardant Health Business Overview
Table 53. Guardant Health Multi-Cancer Early Screening Product
Table 54. Guardant Health Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 55. Guardant Health Recent Development
Table 56. Exact Sciences Company Details
Table 57. Exact Sciences Business Overview
Table 58. Exact Sciences Multi-Cancer Early Screening Product
Table 59. Exact Sciences Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 60. Exact Sciences Recent Development
Table 61. Freenome Company Details
Table 62. Freenome Business Overview
Table 63. Freenome Multi-Cancer Early Screening Product
Table 64. Freenome Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 65. Freenome Recent Development
Table 66. Epiginomics AG Company Details
Table 67. Epiginomics AG Business Overview
Table 68. Epiginomics AG Multi-Cancer Early Screening Product
Table 69. Epiginomics AG Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 70. Epiginomics AG Recent Development
Table 71. Bio-techne Company Details
Table 72. Bio-techne Business Overview
Table 73. Bio-techne Multi-Cancer Early Screening Product
Table 74. Bio-techne Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 75. Bio-techne Recent Development
Table 76. ThriveEarlier Detection Company Details
Table 77. ThriveEarlier Detection Business Overview
Table 78. ThriveEarlier Detection Multi-Cancer Early Screening Product
Table 79. ThriveEarlier Detection Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 80. ThriveEarlier Detection Recent Development
Table 81. GRAIL, Inc. Company Details
Table 82. GRAIL, Inc. Business Overview
Table 83. GRAIL, Inc. Multi-Cancer Early Screening Product
Table 84. GRAIL, Inc. Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 85. GRAIL, Inc. Recent Development
Table 86. CellMax life Company Details
Table 87. CellMax life Business Overview
Table 88. CellMax life Multi-Cancer Early Screening Product
Table 89. CellMax life Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 90. CellMax life Recent Development
Table 91. Berry Genomics Company Details
Table 92. Berry Genomics Business Overview
Table 93. Berry Genomics Multi-Cancer Early Screening Product
Table 94. Berry Genomics Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 95. Berry Genomics Recent Development
Table 96. Singlera Genomics Company Details
Table 97. Singlera Genomics Business Overview
Table 98. Singlera Genomics Multi-Cancer Early Screening Product
Table 99. Singlera Genomics Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 100. Singlera Genomics Recent Development
Table 101. Geneseeq Company Details
Table 102. Geneseeq Business Overview
Table 103. Geneseeq Multi-Cancer Early Screening Product
Table 104. Geneseeq Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 105. Geneseeq Recent Development
Table 106. BGI Genomics Company Details
Table 107. BGI Genomics Business Overview
Table 108. BGI Genomics Multi-Cancer Early Screening Product
Table 109. BGI Genomics Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 110. BGI Genomics Recent Development
Table 111. Burning Rock Biotech Limited Company Details
Table 112. Burning Rock Biotech Limited Business Overview
Table 113. Burning Rock Biotech Limited Multi-Cancer Early Screening Product
Table 114. Burning Rock Biotech Limited Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 115. Burning Rock Biotech Limited Recent Development
Table 116. New Horizon Health Limited Company Details
Table 117. New Horizon Health Limited Business Overview
Table 118. New Horizon Health Limited Multi-Cancer Early Screening Product
Table 119. New Horizon Health Limited Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 120. New Horizon Health Limited Recent Development
Table 121. Yeasen Bio Company Details
Table 122. Yeasen Bio Business Overview
Table 123. Yeasen Bio Multi-Cancer Early Screening Product
Table 124. Yeasen Bio Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 125. Yeasen Bio Recent Development
Table 126. Hangzhou Aoru Biotech Company Details
Table 127. Hangzhou Aoru Biotech Business Overview
Table 128. Hangzhou Aoru Biotech Multi-Cancer Early Screening Product
Table 129. Hangzhou Aoru Biotech Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 130. Hangzhou Aoru Biotech Recent Development
Table 131. Amoy Diagnostics Co., Ltd. Company Details
Table 132. Amoy Diagnostics Co., Ltd. Business Overview
Table 133. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Product
Table 134. Amoy Diagnostics Co., Ltd. Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 135. Amoy Diagnostics Co., Ltd. Recent Development
Table 136. Genetron Health Company Details
Table 137. Genetron Health Business Overview
Table 138. Genetron Health Multi-Cancer Early Screening Product
Table 139. Genetron Health Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 140. Genetron Health Recent Development
Table 141. AnchorDx Company Details
Table 142. AnchorDx Business Overview
Table 143. AnchorDx Multi-Cancer Early Screening Product
Table 144. AnchorDx Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 145. AnchorDx Recent Development
Table 146. Surexam Bio-Tech Co.,Ltd. Company Details
Table 147. Surexam Bio-Tech Co.,Ltd. Business Overview
Table 148. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Product
Table 149. Surexam Bio-Tech Co.,Ltd. Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 150. Surexam Bio-Tech Co.,Ltd. Recent Development
Table 151. HaploX Company Details
Table 152. HaploX Business Overview
Table 153. HaploX Multi-Cancer Early Screening Product
Table 154. HaploX Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 155. HaploX Recent Development
Table 156. HefeiLaierBiotechnologyCo.,Ltd Company Details
Table 157. HefeiLaierBiotechnologyCo.,Ltd Business Overview
Table 158. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Product
Table 159. HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-Cancer Early Screening Business (US$ Million), 2021–2026
Table 160. HefeiLaierBiotechnologyCo.,Ltd Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
Table 164. Authors List of This Report
List of Figures
Figure 1. Multi-Cancer Early Screening Picture
Figure 2. Global Multi-Cancer Early Screening Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Multi-Cancer Early Screening Market Share by Type: 2025 vs 2032
Figure 4. cfDNA Methylation Features
Figure 5. Low-pass WGS Features
Figure 6. Protein Marker Combination Features
Figure 7. Multi-omics Integrated Analysis Features
Figure 8. Global Multi-Cancer Early Screening Market Size Comparison by Commercial Mode (US$ Million), 2021–2032
Figure 9. IVD（In Vitro Diagnostics） Features
Figure 10. LDT (Laboratory Developed Test) Features
Figure 11. Global Multi-Cancer Early Screening Market Size by Application (US$ Million), 2021–2032
Figure 12. Global Multi-Cancer Early Screening Market Share by Application: 2025 vs 2032
Figure 13. Medical Institutions Case Studies
Figure 14. Physical Examination Centers Case Studies
Figure 15. Multi-Cancer Early Screening Report Years Considered
Figure 16. Global Multi-Cancer Early Screening Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 17. Global Multi-Cancer Early Screening Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Multi-Cancer Early Screening Market Share by Region: 2025 vs 2032
Figure 19. Global Multi-Cancer Early Screening Market Share by Players in 2025
Figure 20. Global Multi-Cancer Early Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by Multi-Cancer Early Screening Revenue in 2025
Figure 22. North America Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. North America Multi-Cancer Early Screening Market Share by Country (2021–2032)
Figure 24. United States Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Canada Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Europe Multi-Cancer Early Screening Market Share by Country (2021–2032)
Figure 28. Germany Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. France Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. U.K. Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Italy Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Russia Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Ireland Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Asia-Pacific Multi-Cancer Early Screening Market Share by Region (2021–2032)
Figure 36. China Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Japan Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. South Korea Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Southeast Asia Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. India Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Australia & New Zealand Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Latin America Multi-Cancer Early Screening Market Share by Country (2021–2032)
Figure 44. Mexico Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Brazil Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Middle East & Africa Multi-Cancer Early Screening Market Share by Country (2021–2032)
Figure 48. Israel Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Saudi Arabia Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. UAE Multi-Cancer Early Screening Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Guardant Health Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 52. Exact Sciences Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 53. Freenome Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 54. Epiginomics AG Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 55. Bio-techne Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 56. ThriveEarlier Detection Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 57. GRAIL, Inc. Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 58. CellMax life Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 59. Berry Genomics Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 60. Singlera Genomics Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 61. Geneseeq Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 62. BGI Genomics Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 63. Burning Rock Biotech Limited Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 64. New Horizon Health Limited Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 65. Yeasen Bio Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 66. Hangzhou Aoru Biotech Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 67. Amoy Diagnostics Co., Ltd. Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 68. Genetron Health Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 69. AnchorDx Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 70. Surexam Bio-Tech Co.,Ltd. Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 71. HaploX Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 72. HefeiLaierBiotechnologyCo.,Ltd Revenue Growth Rate in Multi-Cancer Early Screening Business (2021–2026)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Multi-Cancer Early Screening market size from 2026 to 2032?
The annual compound growth rate of the global Multi-Cancer Early Screening market is 17.0% 2026 to 2032.
Which region is expected to have the highest market share?
Which companies rank high in the global Multi-Cancer Early Screening market?
What was the global market size of Multi-Cancer Early Screening in 2026?
What was the global market size of Multi-Cancer Early Screening in 2032?
Related Reports
Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-Cancer Early Screening market is projected to grow from US$ 1305 million in 2025 to US$ 3858 million by 2032, at a CAGR of 17.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 174
USD 4900.00
(Single User License)
Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-Cancer Early Screening market size was US$ 1305 million in 2025 and is forecast to reach a readjusted size of US$ 3858 million by 2032 with a CAGR of 17.0% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 119
USD 4250.00
(Single User License)
Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1305 million in 2025 and is projected to reach US$ 3858 million, growing at a CAGR of 17.0% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 151
USD 3950.00
(Single User License)
Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 160
USD 3950.00
(Single User License)
Global Multi-Cancer Early Screening Market Research Report 2025
The global market for Multi-Cancer Early Screening was valued at US$ 1115 million in the year 2024 and is projected to reach a revised size of US$ 3346 million by 2031, growing at a CAGR of 17.0% during the forecast period.
Published Date: 2025-07-24
Pages: 103
USD 2900.00
(Single User License)
Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Multi-Cancer Early Screening market is projected to grow from US$ 1115 million in 2024 to US$ 3346 million by 2031, at a CAGR of 17.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-24
Pages: 162
USD 4900.00
(Single User License)
Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Multi-Cancer Early Screening market size was US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Published Date: 2025-07-24
Pages: 120
USD 4250.00
(Single User License)
Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Multi-Cancer Early Screening market is projected to grow from US$ 1305 million in 2025 to US$ 3858 million by 2032, at a CAGR of 17.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 174
USD 4900.00 (Single User License)Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Multi-Cancer Early Screening market size was US$ 1305 million in 2025 and is forecast to reach a readjusted size of US$ 3858 million by 2032 with a CAGR of 17.0% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 119
USD 4250.00 (Single User License)Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1305 million in 2025 and is projected to reach US$ 3858 million, growing at a CAGR of 17.0% from 2026 to 2032.
Published: 2026-03-09
Pages: 151
USD 3950.00 (Single User License)Multi-Cancer Early Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Multi-Cancer Early Screening was estimated to be worth US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 160
USD 3950.00 (Single User License)Global Multi-Cancer Early Screening Market Research Report 2025
The global market for Multi-Cancer Early Screening was valued at US$ 1115 million in the year 2024 and is projected to reach a revised size of US$ 3346 million by 2031, growing at a CAGR of 17.0% during the forecast period.
Published: 2025-07-24
Pages: 103
USD 2900.00 (Single User License)Global Multi-Cancer Early Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Multi-Cancer Early Screening market is projected to grow from US$ 1115 million in 2024 to US$ 3346 million by 2031, at a CAGR of 17.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-24
Pages: 162
USD 4900.00 (Single User License)Global Multi-Cancer Early Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Multi-Cancer Early Screening market size was US$ 1115 million in 2024 and is forecast to a readjusted size of US$ 3346 million by 2031 with a CAGR of 17.0% during the forecast period 2025-2031.
Published: 2025-07-24
Pages: 120
USD 4250.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now